Eye Movement Desensitization and Reprocessing (EMDR) in Complex Psychotrauma

Sponsor
GCS Ramsay Santé pour l'Enseignement et la Recherche (Other)
Overall Status
Completed
CT.gov ID
NCT04594434
Collaborator
(none)
49
1
2
19.4
2.5

Study Details

Study Description

Brief Summary

This study wants to demonstrate the effectiveness of combining a positive memory with "recommended" therapy based on EMDR in reducing the disturbance that patients with complex psychotrauma may experience. The positive memory will be called "benevolent memory" (SB) or "less worse memory" (SMP).

Condition or Disease Intervention/Treatment Phase
  • Other: Scale SUD
  • Other: VOC scale
  • Other: DES II scale
N/A

Detailed Description

This is an interventional study, prospective, exploratory, comparative, randomized, controlled versus reference treatment protocol, open.

Patients will be seen 16 times for the purposes of the study. They will be hospitalized during therapy. Discharge from hospitalization occurs during follow-up depending on the patient's condition.

They will be evaluated over a period of 4 to 6 weeks between the start (Day 0 = Week 1) and the end of treatment (visit week 12). These visits will coincide with treatment sessions with the EMDR ± SB / SMP protocol, as part of the support of their complex psychotrauma. At the end of treatment, the patient will be evaluated during follow-up visits at Month 1, Month 3 and Month 6.

Study Design

Study Type:
Interventional
Actual Enrollment :
49 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Efficiency of the Use of Benevolent Memories in the EMDR Protocol in Complex Psychotrauma (Benevolence Study)
Actual Study Start Date :
Dec 12, 2020
Actual Primary Completion Date :
Jul 26, 2022
Actual Study Completion Date :
Jul 26, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: protocol EMDR + SB / SMP protocol (adjusted)

Association of a positive memory with the "recommended" therapy based on EMDR.

Other: Scale SUD
Subjective Units of Distress Scale ou Subjective Units of Disturbance Scale is a scale of subjective appreciation of emotions

Other: VOC scale
The VOC (Validity Of Cognition) scale is a scale of value given to cognition.

Other: DES II scale
The Dissociative Experiences Scale (DES), which is translated as the Dissociative Experiences Scale, is a self-questionnaire to assess the frequency of various dissociative symptoms in the patient's daily life.

Active Comparator: protocol EMDR (standard).

"recommended" therapy based on EMDR.

Other: Scale SUD
Subjective Units of Distress Scale ou Subjective Units of Disturbance Scale is a scale of subjective appreciation of emotions

Other: VOC scale
The VOC (Validity Of Cognition) scale is a scale of value given to cognition.

Other: DES II scale
The Dissociative Experiences Scale (DES), which is translated as the Dissociative Experiences Scale, is a self-questionnaire to assess the frequency of various dissociative symptoms in the patient's daily life.

Outcome Measures

Primary Outcome Measures

  1. Effectiveness of the combination of SB and / or PMS with EMDR technique on reducing the disturbance experienced by patients with complex psychotrauma. [6 months]

    Percentage of patients with a 50% reduction in the SUD score(44/5000 measured by the SUD scale ranging from 0 to 10) at the end of the 3rd "active" EMDR session compared to the pre-treatment score of the 1st "active" session

Secondary Outcome Measures

  1. Disturbance felt [6 months]

    The % of patients responding to therapy (with SUD scores = 0 and VOC = 7) at M1, M3 and M6 will be compared between the 2 groups by a Cochran-Mantel-Haenszel test.

  2. Level of dissociation [6 months]

    The change in the level of dissociation by the DES II scale (score from 0 to 100) after therapy will be compared between the 2 groups by an analysis of covariance with adjustment for the score at inclusion;

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient suffering from a combination of a period of complex trauma and a disturbance triggered by situations in adulthood;

  • Having signed an informed consent form to participate in the study.

Exclusion Criteria:
  • Protected patient (under legal protection, or deprived of liberty by judicial or administrative decision);

  • Patient seeking legal benefit from participating in the study;

  • Patient previously treated with EMDR;

  • Patient unable to understand the information related to the study (linguistic, psychological, cognitive reason, etc.);

  • Untreated epileptic patient;

  • Patient with severe oculomotor disorders;

  • Patient in hypomanic phase;

  • Patient treated with high dose corticosteroids;

  • Patient with alcohol and / or drug misuse in the 7 days preceding inclusion;

  • Pregnant or likely to be (of childbearing age, without effective contraception) or breastfeeding;

  • Patient participating in another clinical trial, or in a period of exclusion from another clinical trial;

  • Patient not beneficiary of a social security scheme.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clinique d'Yveline Vieille-eglise-en Yvelines France

Sponsors and Collaborators

  • GCS Ramsay Santé pour l'Enseignement et la Recherche

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
GCS Ramsay Santé pour l'Enseignement et la Recherche
ClinicalTrials.gov Identifier:
NCT04594434
Other Study ID Numbers:
  • 2020-A01914-35
First Posted:
Oct 20, 2020
Last Update Posted:
Aug 17, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 17, 2022